MCI’s expertise includes:

• New Radiotracers: Based on a sponsor's therapeutic scaffold, MCI provides proprietary compound libraries designed for radiolabeling. After screening for target binding, a compound is selected and MCI provides a demonstration radiolabeled compound.
• Literature Radiotracers: MCI provides cold standards and radiolabeling precursors for compounds that are not commercially available.
• Specialty ³H-labeled compounds. MCI provides tritiated compounds synthesized by novel, compound-specific reactions.
• MCI works to commercialize technologies Vasdev and Josephson have developed. These include methods of efficiently targeting radioisotopes to tumors with peritumoral injection followed by interstitial diffusion, radiolabeling procedures for tau-binding 18F tracers, and hypervalent iodine techniques for radiofluorination.